NBIX vs NYT · P/E 45, rev $1.77B vs P/E 32, rev $762.5M
Neurocrine Biosciences Inc (NBIX) versus New York Times Company (NYT) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
New York Times Company (NYT) is a publishing company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported NYT revenue for 2026-06-30 was $762.5M. Net income was $93.4M. Revenue was up 7.1% from 2026-03-31 to 2026-06-30. NYT currently screens at market cap $12.05B and trailing P/E 32.0.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NYT currently screens at market cap $12.05B and trailing P/E 32.0.
Not investment advice. Open the NBIX and NYT stock pages for the full models.
Not investment advice.